Tonight, the company learned that here in the US, the FDA has followed suit. Here's a bit, from Ed Silverman' crew, at STAT:
. . . .The road to approval has been long for this vaccine, which will likely be stockpiled by some countries — the United States among them — as a hedge against a possible bioterrorism attack.
The vaccine is also likely to make up a substantial portion of an emergency stockpile for outbreaks being put together by Gavi, the Vaccine Alliance, for use in outbreaks. Gavi recently announced plans to establish a 500,000-dose stockpile. The Merck vaccine, given in a single dose, generates a quick immune response, with protection occurring within about 10 days. Those two features make it attractive as a tool for battling an outbreak.
Work on the vaccine stretches back to the 1990s, when a Yale University researcher, John “Jack” Rose, turned a virus that infects livestock — vesicular stomatitis virus — into a vector that could be used for vaccines. His work was expanded upon by scientists at Canada’s National Microbiology Laboratory in the early and mid-2000s. . . .
This is indeed excellent news -- for humanity. Be excellent to one another. . . for we are all we have, one another. . . .
नमस्ते
No comments:
Post a Comment